^
Association details:
| Biomarker: | FGFR1 amplification |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | fexagratinib (ABSK091) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.
Published date:
05/20/2015
Excerpt:
This is a phase II Simon 2 stage design for patients (pts) with FGFR1 (HER2 negative breast/NSCLC) or FGFR2 (gastroesophageal) amplified tumors treated with AZD4547 80mg twice daily...Confirmed RR was 33% (3/9) in FGFR2 amplified GC, and 12.5% (1/8) FGFR1 amplified BC...
DOI:
10.1200/jco.2015.33.15_suppl.2508
Trial ID:
